DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a note issued to investors on Wednesday. The brokerage set a “hold” rating on the stock.

DBVT has been the subject of a number of other reports. HC Wainwright lifted their price objective on DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, October 24th. JMP Securities reiterated a “market outperform” rating and set a $10.00 price target on shares of DBV Technologies in a research report on Tuesday, December 10th.

DBV Technologies Stock Performance

Shares of DBVT opened at $3.25 on Wednesday. The firm has a market capitalization of $66.85 million, a price-to-earnings ratio of -0.72 and a beta of 0.64. DBV Technologies has a 52 week low of $2.20 and a 52 week high of $9.73. The business’s fifty day moving average price is $3.34 and its two-hundred day moving average price is $3.87.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.